Inactive Instrument

CymaBay Therapeutics, Inc.

CBAY

US23257D1037

Biotechnology & Medical Research

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index

March 21, 2024

Latest news about CymaBay Therapeutics, Inc.

Gilead Sciences Completes $4.3 Billion Cymabay Acquisition	Mar. 22	MT
CymaBay Therapeutics, Inc. Announces Board Changes	Mar. 22	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Composite Index	Mar. 21	CI
Gilead Sciences, Inc. completed the acquisition of CymaBay Therapeutics, Inc..	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Pharmaceuticals Select Industry Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P TMI Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from S&P Global BMI Index	Mar. 21	CI
CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from NASDAQ Biotechnology Index	Mar. 14	CI
Gilead Sciences Says Antitrust Waiting Period for CymaBay Therapeutics Deal Expires	Mar. 11	MT
CymaBay Says European Medicines Agency to Review Marketing Authorization Application for Seladelpar	Mar. 04	MT
CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis	Mar. 04	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
CymaBay Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Leerink Partners Downgrades CymaBay Therapeutics to Market Perform From Outperform, Adjusts PT to $32.50 From $26	Feb. 20	MT
UBS Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts Price Target to $32.50 From $25	Feb. 14	MT
LifeSci Capital Downgrades CymaBay Therapeutics to Market Perform From Outperform	Feb. 14	MT
Piper Sandler Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $33	Feb. 14	MT
North American Morning Briefing :Stock Futures -2-	Feb. 14	DJ
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy on Heels of Announced Sale to Gilead Sciences, Raises PT to $32.50 From $29	Feb. 13	MT
B. Riley Downgrades CymaBay Therapeutics to Neutral From Buy	Feb. 13	MT
JonesTrading Downgrades CymaBay Therapeutics to Hold From Buy	Feb. 13	MT
Cantor Fitzgerald Downgrades CymaBay Therapeutics to Neutral From Overweight, Adjusts PT to $32.50 From $30	Feb. 13	MT
William Blair Downgrades CymaBay Therapeutics to Market Perform From Outperform	Feb. 13	MT
BTIG Downgrades CymaBay Therapeutics to Neutral From Buy	Feb. 13	MT
HC Wainwright Downgrades CymaBay Therapeutics to Neutral From Buy, Adjusts PT to $32.50 From $28	Feb. 13	MT

Chart CymaBay Therapeutics, Inc.

Duration

Period

More charts

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with liver and other chronic diseases. The Company's lead product candidate, seladelpar (MBX-8025), is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARd), a nuclear receptor that regulates genes directly or indirectly involved in the synthesis of bile acids/sterols, metabolism of lipids and glucose, inflammation and fibrosis. The Company is focused on developing seladelpar for the treatment of primary biliary cholangitis (PBC), an autoimmune disease that causes progressive destruction of the bile ducts in the liver resulting in impaired bile flow (cholestasis) and inflammation.

Sector

Biotechnology & Medical Research

Related indices

Russell 2000

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs